DOP77: Effect of Inflammatory Bowel Disease and Related Medications on COVID-19 Incidence, Disease Severity, and Outcome -The Israeli ExperienceECCO'21 VirtualYear: 2021
Authors: Richter, V.(1);Bermont, A.(1);Cohen, D.L.(1);Broide, E.(1);Shirin, H.(1)
(1)Shamir Medical Center, Gastroenterology, Tzerifin, Israel
DOP78: The differential diagnosis and clinicopathological spectrum of Inflammatory Bowel Disease: An interesting and informative ECCO topical reviewECCO'21 VirtualYear: 2021
Authors: Feakins , R.M.(1); Torres, J.(2); Borralho-Nunes, P.(3,4); Burisch, J.(5); Cúrdia Gonçalves, T.(6,7,8); De Ridder, L.(9); Driessen, A.(10); Lobatón, T.(11); Menchén, L.(12,13,14); Mookhoek, A.(15); Noor, N.(16); Svrcek, M.(17); Villanacci, V.(18); Zidar, N.(19); Tripathi, M.(20)
(1)Department of Cellular Pathology, Royal Free London NHS Trust, London, United Kingdom;(2)Department of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal;(3)Department of Pathology, Hospital Cuf Descobertas, Lisbon, Portugal;(4)Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal;(5)Gastrounit, medical division, Hvidovre Hospital, University of Copenhagen, Denmark;(6)Department of Gastroenterology, Hospital da Senhora da Oliveira, Guimarães, Portugal;(7)School of Medicine, University of Minho, Braga/Guimarães, Portugal;(8) ICVS/3B’s–PT Government Associate Laboratory, Braga/Guimarães, Portugal;(9)Department of Paediatric Gastroenterology, Erasmus MC Sophia Children’s Hospital, University Medical Center Rotterdam, The Netherlands;(10)Department of Pathology, University Hospital Antwerp, University Antwerp, Edegem, Belgium;(11)Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium;(12)Department of Digestive System Medicine, Hospital General Universitario-Insitituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain;(13)Department of Medicine, Universidad Complutense, Madrid, Spain;(14)Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain;(15)Department of Pathology, Amsterdam UMC, Amsterdam, The Netherlands;(16)Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom;(17)Department of Pathology, Sorbonne Université, AP-HP, Saint-Antoine hospital, Paris, France;(18)Departments of Histopathology, Spedali Civili and University of Brescia, Brescia, Italy;(19)Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia;(20)Department of Histopathology, Cambridge Biomedical Campus, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; TR Clinicopathological spectrum and differential diagnosis of IBD
DOP79: Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case SeriesECCO'21 VirtualYear: 2021
Authors: Albshesh, A.(1);Eder, P.(2);Ribaldone , D.G.(3);Oldenburg, B.(4);De Boer, N.K.(5);Mantzaris, G.J.(6); Savarino, E.V.(7);Dragoni , G.(8);Weisshof, R.(9);Truyens, M.(10);Festa, S.(11);Maillard, M.H.(12);Capirchio , L.(13);Filip, R.(14);Kopylov, U.(1)
(1)Sheba Medical Center and Sackler School of Medicine- Tel-Aviv University, Department of Gastroenterology, Tel Aviv, Israel;(2)Heliodor Święcicki University Hospital, Department of Gastroenterology- Dietetics and Internal Medicine- Poznań University of Medical Sciences, Poznań, Poland;(3)University of Turin, Department of Medical Sciences- Division of Gastroenterology, Turin, Italy;(4)University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands Antilles;(5)Amsterdam UMC, Department of Gastroenterology and Hepatology- Vrije Universiteit Amsterdam- Amsterdam Gastroenterology Endocrinology Metabolism Research Insitute AGEM, Amsterdam, Netherlands Antilles;(6)Evangelismos General Hospital of Athens, Department of Gastroenterology, Athen, Greece;(7)University of Padua, Division of Gastroenterology- Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(8)Careggi University Hospital, IBD Referral Center- Department of Gastroenterology, Florence, Italy;(9)Rambam Health Care Campus, Department of Gastroenterology-, Haifa, Israel;(10)Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium;(11)San Filippo Neri Hospital, IBD Unit- Gastroenterology Division, Rome, Italy;(12)Lausanne University Hospital- Crohn and Colitis Center- Gastroentérologie Beaulieu SA, Division of Gastroenterology and Hepatology, Lausanne, Swaziland;(13)Université Catholique de Louvain- Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Department of Gastroenterology, Yvoir, Belgium;(14)Faculty of Medicine- University of Rzeszow, Department of Gastroenterology with IBD Unit of Clinical Hospital No 2 im. Św. Jadwigi Królowej, Rzeszow, Poland
DOP80: Automatic detection of ulcers and erosions in PillCam™ Crohn’s capsule using a convolutional neural networkECCO'21 VirtualYear: 2021
Authors: SaraivaJr., M.(1);Ribeiro, T.(1);Afonso, J.(1);Cardoso, H.(1);Ferreira, J.(2);Andrade, P.(1);Parente, M.(2);Jorge, R.(2);Lopes, S.(1);Macedo, G.(1)
(1)Centro Hospitalar Universitário de S. João- EPE, Gastroenterology, Porto, Portugal;(2)Faculdade de Engenharia da Universidade do Porto, Mechanical Engineering, Porto, Portugal
DOP81: Quality improvement by semi-automated benchmarking of a core outcome quality indicator set in Inflammatory Bowel Disease: A multicentric feasibility studyECCO'21 VirtualYear: 2021
Authors: Bossuyt, P.(1);Baert, D.(2);Baert, F.(3);Hoefkens, E.(1);Huys, I.(2);Lembrechts, N.(1);De Jonckere, E.(3);Dewint, P.(2);Pouillon, L.(1)
(1)Imelda General Hospital Bonheiden, Department of Gastroenterology, Bonheiden, Belgium;(2)AZ Maria Middelares, Gastroenterology, Gent, Belgium;(3)AZ Delta, Gastroenterology, Rumbeke, Belgium
DOP82: Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION studyECCO'21 VirtualYear: 2021
Authors: Loftus- Jr, E.(1);Vermeire, S.(2);Feagan, B.(3);Yun, C.(4);Hsieh, J.(4);Liu, X.(4);Zhao, S.(4);Moerch, U.(5);Sandborn, W.J.(6);Hibi, T.(7)
(1)Mayo Clinic, Department of Internal Medicine- Department of Gastroenterology and Hepatology, Rochester- MN, United States;(2)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(3)Western University, Department of Medicine- Division of Gastroenterology, London- ON, Canada;(4)Gilead Sciences, Inc., Foster City, United States;(5)Gilead Sciences, Inc., Copenhagen, Denmark;(6)University of California, Department of Medicine, San Diego- La Jolla- CA, United States;(7)Kitasato Institute Hospital- Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan
DOP83: Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term ExtensionECCO'21 VirtualYear: 2021
Authors: Abreu, M.T.(1);Danese, S.(2);Sandborn, W.J.(3);Miao, Y.(4);Tikhonov, I.(4);Zhang, H.(4);Panaccione, R.(5);Hisamatsu, T.(6);Scherl, E.J.(7);Leong, R.W.(8);Rowbotham, D.S.(9);Arasaradnam, R.P.(10);Afif, W.(11);Peyrin-Biroulet, L.(12);Sands, B.E.(13);Marano, C.(4)
(1)University of Miami Miller School of Medicine, Department of Medicine, Miami, United States;(2)Istituto Clinico Humanitas, Department of Gastroenterology, Milano, Italy;(3)University of California San Diego, Division of Gastroenterology, San Diego, United States;(4)Janssen Research & Development- LLC., Immunology, Spring House, United States;(5)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(6)Kyorin University School of Medicine, Third Department of Internal Medicine, Tokyo, Japan;(7)New York Presbyterian Weill Cornell Medical College, Roberts Center for Inflammatory Bowel Disease, New York, United States;(8)Concord Repatriation General Hospital, Inflammatory Bowel Disease Clinic, Concord, Australia;(9)Auckland City Hospital, Gastroenterology, Auckland, New Zealand;(10)University Hospital Coventry & Warwickshire, GI Medicine, Coventry, United Kingdom;(11)McGill University Health Center, Division of Gastroenterology, Montreal, Canada;(12)Nancy University Hospital- Université de Lorraine, Department of Gastroenterology, Nancy, France;(13)Mount Sinai School of Medicine, Henry D. Janowitz Division of Gastroenterology, New York, United States
DOP84: Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn’s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 studyECCO'21 VirtualYear: 2021
Authors: D'Haens, G.(1);Baert, F.(2);Danese, S.(3);Kobayashi, T.(4);Loftus Jr., E.V.(5);Sandborn, W.J.(6);Dornic, Q.(7);Lindner, D.(7);Kisfalvi, K.(8);Marins, E.G.(8);Vermeire, S.(9)
(1)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(2)AZ Delta, Department of Gastroenterology, Roeselare, Belgium;(3)Humanitas University, Department of Gastroenterology, Milan, Italy;(4)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(5)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;(6)University of California San Diego, Department of Medicine, San Diego, United States;(7)Takeda, Statistical and Quantitative Science, Zurich, Switzerland;(8)Takeda, Global Medical Affairs, Cambridge, United States;(9)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
DOP85: Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance studyECCO'21 VirtualYear: 2021
Authors: Vavricka, S.R.(1);Greuter, T.(2);Cohen, B.L.(3);Reinisch, W.(4);Steinwurz, F.(5);Fellmann, M.(6);Guo, X.(7);Lawendy, N.(7);Paulissen, J.(8);Peyrin-Biroulet, L.(9)
(1)Department of Gastroenterology and Hepatology- University Hospital Zurich, and Center for Gastroenterology and Hepatology, Zürich, Switzerland;(2)Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland;(3)Department of Gastroenterology- Hepatology- and Nutrition, Digestive Disease and Surgery Institute- Cleveland Clinic, Cleveland- Ohio, United States;(4)-, Medical University of Vienna, Vienna, Austria;(5)Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, Brazil;(6)Pfizer Switzerland AG, Zürich, Switzerland;(7)Pfizer Inc, Collegeville, Pennsylvania, United States;(8)Pfizer Inc, New York, New York, United States;(9)Department of Gastroenterology, Inserm U1256 NGERE- Nancy University Hospital- Université de Lorraine, Vandœuvre-lès-Nancy, France
DOP86: Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extensionECCO'21 VirtualYear: 2021
Authors: Scherl, E.J.(1);Rowbotham, D.S.(2);Danese, S.(3);Sandborn, W.J.(4);Miao, Y.(5);Zhang, H.(5);Abreu, M.T.(6);Panaccione, R.(7);Afif, W.(8);Hisamatsu, T.(9);Leong, R.W.(10);Arasaradnam, R.P.(11);Sands, B.E.(12);Marano, C.(5)
(1)New York Presbyterian Weill Cornell Medical College, Roberts Center for Inflammatory Bowel Disease, New York, United States;(2)Auckland City Hospital, Gastroenterology, Auckland, New Zealand;(3)Instituto Clinico Humanitas, Department of Gastroenterology, Milano, Italy;(4)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(5)Janssen Research & Development- LLC, Immunology, Spring House, United States;(6)University of Miami Miller School of Medicine, Department of Medicine, Miami, United States;(7)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(8)McGill University Health Centre, Division of Gastroenterology, Montreal, Canada;(9)Kyorin University School of Medicine, Third Department of Internal Medicine, Tokyo, Japan;(10)Concord Repatriation General Hospital, Inflammatory Bowel Disease Clinic, New South Wales, Australia;(11)University Hospital Coventry and Warwickshire, Gastrointestinal Medicine, Coventry, United Kingdom;(12)Mount Sinai School of Medicine, Henry D. Janowitz Division of Gastroenterology, New York, United States UNIFI
DOP87: Disease clearance as a new therapeutic target in patients with Ulcerative Colitis: A multicenter retrospective cohort studyECCO'21 VirtualYear: 2021
Authors: D'Amico, F.(1);Fiorino, G.(1);Massarini, E.(1);Solitano, V.(1);Guillo, L.(2);Allocca, M.(1);Furfaro, F.(3);Zilli, A.(3);Bonovas, S.(1);Peyrin-Biroulet, L.(4);Danese, S.(5)
(1)Humanitas University, Department of Biomedical Sciences, Milan, Italy;(2)University Hospital of Nancy- Unicersity of Lorraine, Department of Gastroenterology and Inserm NGERE U1256, Vandoeuvre-lès-Nancy, France;(3)Humanitas Research Hospital- IRCCS, IBD center, Milan, Italy;(4)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology and Inserm NGERE U1256, Vandoeuvre-lès-Nancy, France;(5)IRCCS Humanitas Research Hospital, Department of Gastroenterology, Rozzano, Italy
DOP88: Effect of risankizumab on patient-reported outcomes in patients with Crohn’s Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trialsECCO'21 VirtualYear: 2021
Authors: Peyrin-Biroulet, L.(1);Louis, E.(2);Ghosh, S.(3);Lee, S.D.(4);Griffith, J.(5);Wallace, K.(5);Berg, S.(5);Loftus Jr, E.V.(6)
(1)University Hospital of Nancy- Lorraine University, Gastroenterology, Vandoeuvre, France;(2)University Hospital CHU of Liège, Gastroenterology, Liège, Belgium;(3)University of Birmingham, Institute of Translational Medicine, Birmingham, United Kingdom;(4)University of Washington, Department of Medicine- Division of Gastroenterology, Seattle, United States;(5)AbbVie Inc., Health Economics and Outcomes Research, North Chicago, United States;(6)Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States
DOP89: Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trialECCO'21 VirtualYear: 2021
Authors: Zoller, H.(1);Wolf, M.(2);Blumenstein, I.(3);Primas, C.(4);Lindgren, S.(5);Thomsen, L.L.(6);Reinisch, W.(4);Iqbal, T.(7)
(1)Medical University of Innsbruck, Christian Doppler Laboratory of Iron and Phosphate Biology- Department of Medicine I, Innsbruck, Austria;(2)Duke University School of Medicine, Medicine – Nephrology, Durham- NC, United States;(3)University Hospital Frankfurt, Department of Internal Medicine 1, Frankfurt, Germany;(4)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;(5)Clinical Sciences Malmö- Lund University- Sweden, Gastroenterology- Skane University Hospital, Lund, Sweden;(6)Pharmacosmos A/S, Clinical Research & Development, Holbæk, Denmark;(7)Queen Elizabeth Hospital Birmingham, Department of Gastroenterology, Birmingham, United Kingdom
DOP90: Physician global assessment of IBD Activity is associated with COVID-19 severity in patients aged less than 50 yearsECCO'21 VirtualYear: 2021
Authors: Ricciuto, A.(1);Lamb, C.(2,3);Benchimol, E.I.(1);Walker, G.(4);Kennedy, N.(5,6);Kuenzig, M.E.(1);Kaplan, G.(7);Griffiths, A.M.(1);Reinisch, W.(8);Sebastian, S.(9,10)
(1)The Hospital for Sick Children, Division of Gastroenterology Hepatology and Nutrition, Toronto, Canada;(2)Newcastle University, Gastroenterology, Newcastle upon Tyne, United Kingdom;(3)Newcastle Upon Tyne Hospitals NHS Foundation Trust, Gastroenterology, Newcastle upon Tyne, United Kingdom;(4)Torbay and South Devon NHS Foundation Trust, Gastroenterology, Torbay, United Kingdom;(5)University of Exeter, Gastroenterology, Exeter, United Kingdom;(6)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(7)University of Calgary, Gastroenterology, Calgary, Canada;(8)Medical University of Vienna, Gastroenterology, Vienna, Austria;(9)University of Hull, Gastroenterology, Kingston upon Hull, United Kingdom;(10)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Kingston Upon Hull, United Kingdom
N01: Does physical activity positively impact fatigue in individuals with Inflammatory Bowel Disease?ECCO'21 VirtualYear: 2021
Authors: Farrell, D.(1);Bager, P.(2);Bredin, F.(3);Cairnes, V.(4);Forry, M.(5);Gilham, E.(3);Godwin, N.(5);Herdmangrant, R.(6);Ni Dhalaigh, D.(1);O' Shea, T.(7);Sugrue, K.(8);
(1)Munster Technological University, Department of Nursing and Healthcare Sciences, Tralee, Ireland;(2)Aarhus University Hospital, Department of Clinical Medicine - The Department of Hepatology and Gastroenterology, Aarhus, Denmark;(3)The Queen Elizabeth Hospital- NHS Foundation Trust, Department of Gastroenterology, Kings Lynn, United Kingdom;(4)Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;(5)Beaumont Hospital, Department of Gastroenterology, Dublin, Ireland;(6)Kingston Hospital NHS Foundation Trust, Research and Innovation Department, Kingston upon Thames, United Kingdom;(7)Munster Technological University, Department of Business, Tralee, Ireland;(8)Mercy University Hospital, Department of Gastroenterology, Cork, Ireland
N03: Information flow experiences during COVID-19 in IBD patients: a prospective observational studyECCO'21 VirtualYear: 2021
Authors: Geens, P.(1);De Dycker, E.(1);Paps, A.(1);Lambrechts, T.(1);Sabino, J.(1);Ferrante, M.(1);Vermeire, S.(1);
(1)KU Leuven, gastro enterology, Leuven, Belgium
N04: Being an IBD Clinical Nurse Specialist in the UK National Health Service: Challenges, Stressors and Coping MechanismsECCO'21 VirtualYear: 2021
Authors: Dibley, L.(1);Kemp, K.(2);Duncan, J.(3);Mason, I.(4);Lisa, Y.(5);
(1)University of Greenwich, Faculty of Education- Health and Human Sciences, London, United Kingdom;(2)Manchester Royal Infirmary, Department of Gastroenterology, Manchester, United Kingdom;(3)Takeda, Nurse Education, London, United Kingdom;(4)Royal Free London NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(5)London North West University Healthcare NHS Trust, St Mark's Hospital- IBD Unit, London, United Kingdom
N05: A Systematic Review of Self-Management Intervention Study for Patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Lizawa, M.(1);Hirose, L.(1);Tairaka, A.(1);Maya, N.(2);
(1)Takeda Pharmaceutical Company Limited., Japan Medical Office, Tokyo, Japan;(2)Mukogawa Women’s University, School of Nursing, Hyogo, Japan
N06: Patient perspectives on the role of the IBD nurse and telemedicine during COVID-19 pandemic: results from a Belgian tertiary IBD unitECCO'21 VirtualYear: 2021
Authors: Dewitte, G.(1);Geldof, J.(1,2);Truyens, M.(1,2);Lobaton, T.(1,2);
(1)UZ Gent, Gastro-enterology, Gent, Belgium;(2)Ghent University, IBD research unit – Gastroenterology- Department of Internal Medicine and Pediatrics, Ghent, Belgium
